ARQT
Companies
NASDAQ
Arcutis Biotherapeutics Inc.
Health Care
$13.67
-$0.26 (-1.87%)
Price Chart
Overview
About ARQT
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Market Cap
$838.1M
Volume
30.6M
Avg. Volume
29.9M
P/E Ratio
-14.806123
Dividend Yield
0.00%
Employees
282.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.28
High Correlation
Volatility
High (0.77)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
High Sensitivity
Commodity Prices
High Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ARQT shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$838.1M
Volume30.6M
P/E Ratio-14.81
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
November 7, 2024Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025